Merck says its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.
Merck's heart failure drug misses trial goalsCourtesy Newsvine - business Fri, 06/05/2009 - 07:25
Merck says its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo. Related itemsMerck loses $473M tax appeal in Schering case
Selected first-quarter drug sales for Merck & Co.
FDA says Merck drug successfully fights hepatitis
Samsung SCX-4200 3-in-1 True Multifunction Printer
BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
|
Popular by tags WeekMonth |
Post new comment